Navigation Links
Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing

MADISON, Wis., July 15 /PRNewswire/ -- Cellular Dynamics International (CDI) today announced that it has exclusively in-licensed a US-issued patent portfolio on optimizing the stem cell differentiation selection process and on using heart cells (cardiomyocytes) in drug testing.

The license, obtained from Dr. Loren Field and Indiana University-Purdue University Indianapolis (IUPUI), covers two important concepts for using stem cell-derived cells for drug screening. First, the Field patents cover a cell purification strategy that enables greater than 90 percent purity of any type of cells. Secondly, the Field patents cover the use of stem cell-derived cardiomyocytes for drug testing. Financial terms of the license were not disclosed.

"CDI is building an industrial pipeline and automated process enabling us to plug in different cell types and generate large quantities of purified cells," said Chris Kendrick-Parker, chief commercial officer of CDI. "That is the primary requirement for commercial application of these cells as tools in the pharmacology and toxicity testing market. Similar to our recently announced in-licensed patent portfolio from Mount Sinai School of Medicine, the IUPUI agreement ensures that we have a commercial advantage in this area, providing our customers with the comfort that they are unencumbered when they do business with us."

Brad Fravel, business development manager at Indiana University Research & Technology Corporation said, "As a leader in the pluripotent stem cell field, CDI is a great licensing partner for IUPUI. We are confident CDI will run with this technology, exploiting it to its fullest potential."

The license enables CDI to optimize the process of developing and purifying different cell types created from human pluripotent stem cells, including the company's first commercially available product line, human cardiomyocytes. Under the licensed technology, pluripotent stem cells are engineered to include a selectable "marker." As the stem cells begin to differentiate into different terminal cell types (e.g. heart, blood, neural cells, etc.), the marker allows researchers to identify and select a particular cell type (e.g. heart cells) and produce a highly purified and functional cell population.

The license also covers the use of cardiomyocytes purified through this technology for drug testing. While cardiomyocytes are the company's entree into the market, the company has programs in place for developing multiple cell types, and the Field patents enable the company to develop them into highly purified populations. CDI is using the Field technology in conjunction with the patents it has licensed from the Wisconsin Alumni Research Foundation (WARF), UW-Madison's tech-transfer vehicle, to create a pipeline that mass produces cells for large-scale drug screening campaigns at pharmaceutical companies and for regenerative medicine applications.

In addition the license, which includes patents pending at the European Patent Office, also allows CDI to sublicense to other companies and institutions.

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development and personalized medicine applications. CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools. In addition, it is the leader in iPS technology, the production of pluripotent stem cell lines from adult tissue. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human embryonic stem cell research at the University of Wisconsin-Madison, and Tactics II Ventures, a Wisconsin-based venture capital fund. CDI's facilities are located in Madison, Wisconsin. See

    Joleen Rau
    Senior Director, Marketing & Communications
    Cellular Dynamics International, Inc.
    (608) 310-5142

    Robert E. Flamm, Ph.D.
    Russo Partners LLC
    (212) 845-4226

    Tony Russo
    Russo Partners LLC
    (212) 845-4251

SOURCE Cellular Dynamics International (CDI)
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cellular Dynamics International Reprograms Blood Cells into Stem Cells
2. iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming
3. Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement
4. New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the Worlds Leading Bioenergetics Researchers
5. MIT, BU engineer cellular circuits that count events
6. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
7. Orange and Medic4all Launched the Worlds First Cellular Tele-Health Service
8. MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting
9. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11
10. Cellumen to Collaborate With the NCTR of the FDA to Apply Cellular Systems Biology (CSB(TM)) to Predictive Toxicology
11. New insights into cellular reprogramming revealed by genomic analysis
Post Your Comments:
(Date:11/27/2015)... /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ), a ... closed the sale of its global contrast media and ... in a transaction valued at approximately $270 million. The ... total of approximately 1,000 employees spread across the globe, ... area. This entire workforce and the manufacturing ...
(Date:11/26/2015)... 26, 2015 --> ... in imaging technologies, announced today that it has received a ... the Horizon 2020 European Union Framework Programme for Research and ... trial in breast cancer. , --> ... --> --> The study aims to ...
(Date:11/25/2015)... Studies reveal the differences in species of ... way for more effective treatment for one of the most ... --> --> Gum disease is ... yet relatively little was understood about the bacteria associated with ... by researchers from the WALTHAM Centre for Pet Nutrition together ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... of Black Aerospace Professionals (OPBAP) has been formalized with the signing of a ... leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, ...
Breaking Biology Technology:
(Date:11/17/2015)... 2015  Vigilant Solutions announces today that Mr. ... Directors. --> --> ... the partnership at TPG Capital, one of the largest ... Billion in revenue.  He founded and led TPG,s Operating ... companies, from 1997 to 2013.  In his first role, ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
(Date:11/12/2015)... Nov. 12, 2015  Arxspan has entered into ... and Harvard for use of its ArxLab cloud-based ... tools. The partnership will support the institute,s efforts ... chemical research information internally and with external collaborators. ... for managing the Institute,s electronic laboratory notebook, compound ...
Breaking Biology News(10 mins):